West Pharmaceutical Services, Inc. (WST) Reaches $89.95 After 6.00% Down Move; Gotham Asset Management Has Lowered Its Mylan N V (MYL) Stake

February 15, 2018 - By David King

The stock of West Pharmaceutical Services, Inc. (NYSE:WST) is a huge mover today! The stock decreased 5.36% or $5.09 during the last trading session, reaching $89.95. About 362,999 shares traded or 11.90% up from the average. West Pharmaceutical Services, Inc. (NYSE:WST) has risen 33.75% since February 15, 2017 and is uptrending. It has outperformed by 17.05% the S&P500.The move comes after 8 months negative chart setup for the $6.68 billion company. It was reported on Feb, 15 by Barchart.com. We have $84.55 PT which if reached, will make NYSE:WST worth $400.74 million less.

Gotham Asset Management Llc decreased Mylan N V (MYL) stake by 92.38% reported in 2017Q3 SEC filing. Gotham Asset Management Llc sold 770,163 shares as Mylan N V (MYL)’s stock declined 9.77%. The Gotham Asset Management Llc holds 63,497 shares with $1.99 million value, down from 833,660 last quarter. Mylan N V now has $22.12B valuation. The stock decreased 0.24% or $0.1 during the last trading session, reaching $41.24. About 1.21M shares traded. Mylan N.V. (NASDAQ:MYL) has declined 7.73% since February 15, 2017 and is downtrending. It has underperformed by 24.43% the S&P500.

Since December 8, 2017, it had 0 buys, and 1 insider sale for $2.08 million activity. FEDERICI WILLIAM J also sold $2.08M worth of West Pharmaceutical Services, Inc. (NYSE:WST) on Friday, December 8.

Among 6 analysts covering West Pharmaceutical Services (NYSE:WST), 3 have Buy rating, 0 Sell and 3 Hold. Therefore 50% are positive. West Pharmaceutical Services had 14 analyst reports since August 4, 2015 according to SRatingsIntel. As per Wednesday, September 21, the company rating was downgraded by Wells Fargo. The stock of West Pharmaceutical Services, Inc. (NYSE:WST) has “Outperform” rating given on Friday, October 27 by Wells Fargo. The rating was initiated by Janney Capital on Friday, January 8 with “Buy”. The stock of West Pharmaceutical Services, Inc. (NYSE:WST) has “Hold” rating given on Monday, September 11 by Jefferies. The firm has “Hold” rating by Jefferies given on Thursday, July 27. The stock of West Pharmaceutical Services, Inc. (NYSE:WST) has “Hold” rating given on Tuesday, October 17 by Bank of America. The stock has “Hold” rating by Jefferies on Thursday, June 29. The firm has “Hold” rating by Jefferies given on Tuesday, June 6. The firm earned “Outperform” rating on Friday, October 28 by Wells Fargo. Jefferies upgraded West Pharmaceutical Services, Inc. (NYSE:WST) rating on Friday, September 15. Jefferies has “Buy” rating and $115 target.

West Pharmaceutical Services, Inc. manufactures and sells packaging components and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, and internationally. The company has market cap of $6.68 billion. The company??s Proprietary Products segment offers stoppers and seals for injectable packaging systems; and syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies. It has a 35.99 P/E ratio. It also provides drug containment solutions, including CZ vials, syringes, and cartridges; and self-injection systems, as well as specialized testing services for drug packaging, devices, and administration systems.

Investors sentiment decreased to 1.33 in Q3 2017. Its down 0.28, from 1.61 in 2017Q2. It turned negative, as 31 investors sold West Pharmaceutical Services, Inc. shares while 76 reduced holdings. 42 funds opened positions while 100 raised stakes. 68.09 million shares or 1.49% more from 67.09 million shares in 2017Q2 were reported. Weaver C Barksdale & Incorporated holds 0.01% or 88 shares in its portfolio. Teachers Retirement Of The State Of Kentucky accumulated 16,950 shares. Fdx Inc holds 0.02% of its portfolio in West Pharmaceutical Services, Inc. (NYSE:WST) for 7,104 shares. Ami Asset Management Corporation holds 2.29% or 336,102 shares in its portfolio. Oppenheimer And Commerce holds 0.04% in West Pharmaceutical Services, Inc. (NYSE:WST) or 16,600 shares. Natl Bank Of Mellon has invested 0.02% in West Pharmaceutical Services, Inc. (NYSE:WST). State Of Tennessee Treasury Department owns 80,000 shares. Tiaa Cref Investment Management Ltd Llc stated it has 135,913 shares. Contravisory Management reported 2,117 shares. Thrivent Financial For Lutherans holds 137,218 shares or 0.05% of its portfolio. Bluemountain Mgmt Limited Liability reported 0.04% in West Pharmaceutical Services, Inc. (NYSE:WST). Proshare Advisors Ltd Liability accumulated 106,120 shares. 34,985 were reported by Castleark Mngmt Ltd Liability. Bessemer Gru Inc Inc invested 0% of its portfolio in West Pharmaceutical Services, Inc. (NYSE:WST). Cambridge Invest Rech Advsrs Incorporated reported 3,883 shares or 0.01% of all its holdings.

Gotham Asset Management Llc increased Anika Therapeutics Inc (NASDAQ:ANIK) stake by 9,101 shares to 42,927 valued at $2.49M in 2017Q3. It also upped Phibro Animal Health Corp (NASDAQ:PAHC) stake by 28,745 shares and now owns 66,880 shares. Te Connectivity Ltd (NYSE:TEL) was raised too.

Among 21 analysts covering Mylan Inc. (NASDAQ:MYL), 13 have Buy rating, 0 Sell and 8 Hold. Therefore 62% are positive. Mylan Inc. had 65 analyst reports since July 27, 2015 according to SRatingsIntel. As per Monday, December 4, the company rating was maintained by UBS. The rating was initiated by Barclays Capital with “Equal Weight” on Monday, September 21. The firm has “Buy” rating given on Monday, August 17 by Zacks. The firm has “Outperform” rating by Leerink Swann given on Saturday, August 29. Mizuho maintained it with “Buy” rating and $37.0 target in Monday, October 23 report. As per Tuesday, February 6, the company rating was maintained by BMO Capital Markets. The firm earned “Buy” rating on Tuesday, July 28 by Deutsche Bank. Citigroup maintained Mylan N.V. (NASDAQ:MYL) on Thursday, January 4 with “Buy” rating. The rating was downgraded by Citigroup to “Neutral” on Thursday, January 5. The stock of Mylan N.V. (NASDAQ:MYL) has “Market Perform” rating given on Monday, July 27 by Cowen & Co.

Investors sentiment decreased to 0.33 in Q3 2017. Its down 1.00, from 1.33 in 2017Q2. It is negative, as 3 investors sold MYL shares while 0 reduced holdings. 1 funds opened positions while 0 raised stakes. 155,019 shares or 7.99% less from 168,486 shares in 2017Q2 were reported. Vantage Inv Advisors Ltd Limited Liability Company reported 0.01% of its portfolio in Mylan N.V. (NASDAQ:MYL). Gulf Int Bancorporation (Uk) invested in 0.06% or 139,930 shares.

Analysts await Mylan N.V. (NASDAQ:MYL) to report earnings on March, 7. They expect $1.40 EPS, down 10.83% or $0.17 from last year’s $1.57 per share. MYL’s profit will be $751.02M for 7.36 P/E if the $1.40 EPS becomes a reality. After $1.10 actual EPS reported by Mylan N.V. for the previous quarter, Wall Street now forecasts 27.27% EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.